Myriad Genetics, Salt Lake City, says the results of a large-scale study demonstrate that the company’s Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer.1
“This study demonstrates that the Prolaris test effectively identified those men with localized prostate cancer who progressed to metastatic disease,” says study investigator Stephen Bardot, MD, chairman of urology and associate medical director for surgical services at the Oschner Clinic. “Importantly, the Prolaris test provided critical information that can be used to determine which men with localized prostate cancer are candidates for active surveillance, and which men should receive definitive therapy with surgery or radiation at the time of diagnosis.”
Prolaris is a genetic test that directly measures tumor cell growth. Paired with a patient’s prostate-specific antigen (PSA) test and Gleason score, Prolaris reveals the level of aggressiveness of a patient’s prostate cancer. PSA and Gleason scores are only able to indicate how far a patient’s cancer has progressed thus far. When they are combined with a Prolaris test score, however, patients get an accurate assessment of how aggressively that cancer will progress over the next 10 years.
The large, pooled analysis included 1,062 men with localized prostate cancer who were definitively treated with surgery (n = 800) or radiation (n = 262). The primary objective of the study was to evaluate the ability of the Prolaris test (CCP score), and the Prolaris test combined with clinical information (CCR score), to predict 10-year risk of progression to metastatic disease.
The analysis demonstrated that the Prolaris test was the strongest independent predictor of progression to metastatic disease. Men were approximately three times more likely to develop metastatic disease with each unit increase in the Prolaris test score (HR: 2.93; p = 1.8×10–11).
When the Prolaris test score was combined with clinical information, the results were even more highly prognostic (Figure 1). Men were up to four times more likely to develop metastases with each unit of increase in the test score (HR: 4.00; p = 6.3×10–21).
For more information visit Myriad Genetics.
- Canter DJ, Freedland S, Rajamani S, et al. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate Cancer Prostatic Dis. Published online, June 27, 2019; doi: 10.1038/s41391-019-0159-9.
Prostate cancer cells © Paul Hakimata courtesy Dreamstime (ID-18357688).